bpc-157 not approved by fda statement panel backs compounded BPC-157, KPV peptides in win for RFK Jr FDA Panel Narrowly Backs Lifting

Introduction We focused on the stable gastric pentadecapeptide BPC 157 ( Thus, we suggest that one single application of the NO-synthase (NOS) blocker N(G)-nitro-L-arginine methyl ester (L-NAME) may induce retinal ischemia in rats, and that the stable pentadecapeptide BPC 157 may be the therapy, since it may interact with the NO-system and may counteract various adverse effects of L-NAME application (see In the previous eye research studies, BPC 157 counteracts atropine-mydriasis, but it also opposes an immediate and hour-lasting miotic effect of L-NAME in rats and guinea pigs, and participates in pupil control potentially via NO-mediated and cholinergic mechanisms ( This may be essential for the effective counteraction of the damaging effect of the retrobulbar L-NAME application

BPC-157 works on the physical plumbingthe vascular and nerve tissuewhile a peptide like [PT-141]( works on the central nervous system to increase libido

Current obstacles to successful local or systemic delivery of peptides include poor absorption, enzymatic degradation, and mucociliary clearance

503A compounding pharmacies operate differently they fill individual prescriptions for specific patients, under direct provider oversight

[DOI] [PMC free article] [PubMed] [Google Scholar] 53.Han X et al